GLP-1 Peptides for Research: Comparing Research-Grade Incretin Compounds

Written by: Stuart Ratcliff and Kai Reviewed by: Chameleon Peptides Research Team Last reviewed: July 10, 2026

The GLP-1 receptor agonist class has transformed metabolic research and pharmaceutical development. With GLP-1S (CAS 910463-68-2) and GLP-1T (CAS 2023788-19-2) widely discussed in incretin pharmacology, researchers are increasingly interested in the broader GLP-1 peptide landscape, including research-grade analogs used for controlled laboratory comparison.

This article compares the major GLP-1 receptor-targeting peptides relevant to research, with a focus on receptor pharmacology, half-life differences, and what makes each compound distinct.

The GLP-1 Receptor System: A Quick Primer

The glucagon-like peptide-1 (GLP-1) receptor is a G-protein-coupled receptor (GPCR) expressed in the pancreas, brain, gastrointestinal tract, heart, and kidney. When activated, it:

Stimulates glucose-dependent insulin secretion (incretin effect)
Suppresses glucagon release
Slows gastric emptying
Reduces appetite through hypothalamic signaling

Natural GLP-1 has a half-life of roughly 2 minutes – it’s rapidly degraded by dipeptidyl peptidase-4 (DPP-4). Every therapeutic and research GLP-1 peptide is designed to resist this degradation in some way.

But the newer generation doesn’t stop at GLP-1. Dual and triple agonists target additional incretin receptors:

GIP receptor (glucose-dependent insulinotropic polypeptide)
Glucagon receptor (involved in energy expenditure and lipid metabolism)

This multi-receptor approach is where the most active research is happening.

The Research-Grade GLP-1 Landscape

GLP-1S (GLP-1S Research Reagent)

GLP-1S is the research-grade coded GLP-1S research reagent (CAS 910463-68-2).

Receptor selectivity: GLP-1 receptor only (single agonist)

Key characteristics:

Modified with a C-18 fatty acid chain for albumin binding
Extended half-life reported in published pharmacokinetic literature
The fatty acid chain is what distinguishes it from earlier GLP-1 analogs as earlier long-acting GLP-1 research analogs (which uses a C-16 chain)
Well-characterized pharmacokinetics from extensive clinical development

Research applications:

Glucose metabolism and insulin signaling studies
Appetite regulation and hypothalamic pathway research
Single-receptor control experiments (isolating GLP-1 effects without GIP or glucagon cross-activation)

GLP-1T (GLP-1T Research Reagent)

GLP-1T is the research-grade coded GLP-1T research reagent (CAS 2023788-19-2).

Receptor selectivity: Dual agonist – GLP-1 receptor + GIP receptor

Key characteristics:

39-amino-acid peptide with specific modifications at positions 2, 13, and 17
The GIP receptor activation is what differentiates it from GLP-1S
Half-life: ~5 days (approximately 160 hours)
Dual agonism is used in comparative incretin-pathway research against GLP-1-only models

Research applications:

Dual incretin receptor interaction studies
Comparative GLP-1 vs. GLP-1+GIP experiments
The most relevant comparator for GLP-1S research

GLP-3 (GLP-3 Research Reagent)

GLP-3 is the research-grade coded GLP-3 research reagent – a triple agonist targeting GLP-1, GIP, and glucagon receptors.

Receptor selectivity: Triple agonist – GLP-1 + GIP + Glucagon

Key characteristics:

The first triple incretin receptor agonist to reach advanced clinical development
Glucagon receptor activation adds an energy expenditure component not present in dual agonists
Published development data has made this one of the most closely studied multi-receptor GLP-1-class analogs
Still an active investigational reference compound in published development literature

Research applications:

Triple receptor pharmacology – the frontier of incretin research
Energy expenditure and lipid metabolism alongside glucose regulation
Head-to-head comparison with single and dual agonists

GLP-1C (Research-Grade GLP-1 Variant)

GLP-1C is a research compound targeting the GLP-1 receptor with a distinct modification profile from GLP-1S analogs.

Receptor selectivity: GLP-1 receptor

Research applications:

Comparative studies against GLP-1S analogs
Structure-activity relationship (SAR) research
Concentration-response characterization

Head-to-Head: What Makes Each Different

Compound	Receptors Targeted	Reference Compound	CAS Reference	Research Interest
GLP-1S	GLP-1	GLP-1S	910463-68-2	High – single receptor baseline
GLP-1T	GLP-1 + GIP	GLP-1T	2023788-19-2	Very high – dual agonism
GLP-3	GLP-1 + GIP + Glucagon	GLP-3	2381089-83-2	Highest – triple agonism frontier
GLP-1C	GLP-1	Research compound	N/A	Moderate – SAR studies

The progression from single → dual → triple agonism represents the trajectory of the entire field. Researchers increasingly need access to all three classes for comparative studies.

Why Research-Grade Compounds?

Legitimate researchers sometimes ask why controlled laboratory work uses research-grade compounds rather than commercial pharmaceutical formulations.

A few reasons:

Cost at research scale – commercial pharmaceutical formulations are priced for regulated clinical distribution, not bulk research. Research-grade compounds are significantly more economical for in vitro and animal model work.

Formulation differences – commercial pharmaceutical formulations include excipients, delivery devices, and formulation-specific variables. Research-grade peptides are lyophilized pure compound, better suited for controlled experimental conditions.

Availability – GLP-3 (GLP-3 analog) isn’t yet approved, making research-grade GLP-3 the primary access point for triple agonist research.

Lot consistency – research suppliers provide batch-specific COAs with HPLC and MS data, which is often more useful for documentation in research publications than commercial formulation lot numbers.

Purity and Verification

The GLP-1 peptide class is complex – even small sequence errors or modifications can change receptor binding profiles. Verification is critical:

HPLC purity ≥99% – contaminants in this class can have their own receptor activity
Mass spectrometry confirmation – verifies the correct molecular weight (each analog has a distinct MW)
Third-party COAs – independent lab verification is essential
Proper storage – lyophilized, at -20°C, protected from light

Chameleon Peptides offers GLP-1S, GLP-1T, GLP-3, and GLP-1C with independent Janoshik Analytical verification on each batch. Verification links are provided on product pages.

The Research Frontier

Current areas of active GLP-1 peptide research include:

Triple agonist optimization – tuning the relative potency at each receptor for different metabolic profiles

Neuroprotective applications – GLP-1 receptors are expressed in the brain, and neuroprotective research is expanding

Cardiometabolic pathway research – receptor-signaling studies continue to examine downstream pathway effects

Concentration-response mapping – especially for triple agonists where the published research base is still developing

References

^[1]: Knudsen LB, Lau J. “Long-acting GLP-1 receptor agonist development review.” Front Endocrinol. 2019;10:155.
^[2]: Coskun T, et al. LY3437943 triple GIP, GLP-1, and glucagon receptor agonist pharmacology. Mol Metab. 2022;64:101560.
^[3]: Jastreboff AM, et al. GLP-3 triple-hormone-receptor agonist development data. N Engl J Med. 2023;389(6):514-526.
^[4]: Frias JP, et al. Comparative incretin pharmacology. N Engl J Med. 2023;389(2):137-146.

This article is for informational and educational purposes only. Research peptides are sold for in vitro and preclinical research use only – not for human consumption or therapeutic use.